Top 10 Deals: Five Year Review

In 2021, we started our Top 10 Deals series to answer a question we kept hearing from VCs and LPs: does women's health actually produce exits? Five years and 50 deals later, the answer is clear. It does, and at a scale few predicted.

In 2021, we started our Top 10 Deals series to answer a question we kept hearing from VCs and LPs: does women's health actually produce exits? Five years and 50 deals later, the answer is clear. It does, and at a scale few predicted.

Each year we pick ten transactions that tell us where the market is going: strategic acquisitions, IPOs, private equity buyouts and growth rounds across fertility, maternal health, menopause, oncology, sexual health and more. Before we kick off the 2026 series, we're looking back at what five years of deals have taught us.

‍

Five years, five chapters

Disclosed deal value on our lists went from $4.6B in 2021 to $32.6B in 2025, a 7x increase, after bottoming out at $1.9B in 2023. Here is how each year read at the time.

2025: The IPO window reopened and megadeals arrived

TPG and Blackstone take Hologic private ($18.3B); BillionToOne IPO ($4.4B); Hinge Health IPO ($2.5B); KKR buys Karo Healthcare ($3B); Eli Lilly buys a breast cancer therapeutic ($2.5B); Oura raises $900M at an $11B valuation.

2024: Unicorns and serial acquirers

Boston Scientific buys Axonics ($3.7B); Genmab buys ProfoundBio ($1.8B); Insud Pharma buys Viatris's women's health business ($1.2B); Hologic buys a fibroid treatment company ($350M) and Endomag ($310M); Flo Health and BillionToOne reach unicorn status.

2023: Deals kept closing in the worst M&A market in a decade, but sizes shrank

L Catterton buys Thorne ($680M); Pharmavite buys menopause brand Bonafide ($425M); CooperCompanies buys Cook Medical's OBGYN line; Gilead buys breast cancer biotech XinThera and Cosette buys menopause drug Intrarosa (both undisclosed).

2022: IPOs and SPACs stalled, so M&A carried the year

Carlyle and PAI buy Theramex ($1.4B); Cooper buys Cook Medical's reproductive health portfolio ($875M); Essity buys Knix ($320M); Kimberly-Clark takes majority stake in Thinx ($181M); Ro buys Dadi ($100M); our portfolio company Gennev acquired by Unified Women's Healthcare.

2021: A hot market: SPACs, mergers and medtech

Cooper buys Generate Life Sciences ($1.6B); Lovehoney and WOW Tech merge ($1.2B); Owlet goes public via SPAC (~$1B); Organon buys Alydia Health ($240M); Hologic buys Biotheranostics (~$230M).

‍

Who's buying

This is not every deal in women's health. It covers only the 50 deals featured in our Top 10 Deals series from 2021 to 2025, grouped by buyer or exit type, with disclosed values added up.

‍

Disclosed values only. Deals with undisclosed prices are excluded, so every total is a floor. Healthcare strategics include pharma, medtech, providers and diagnostics. The Lovehoney and WOW Tech merger is counted at the merged group's valuation. Cooper's acquisition of Generate Life Sciences was added to our 2021 list for this review.

‍

What we learned

1. Exits are getting bigger. Exit value on our lists grew from $4.3B in 2021 to $31.7B in 2025, more than 7x. Billion-dollar exits went from zero in 2023 to five in 2025. And even in 2023, when overall M&A hit its lowest level since 2013, women's health deals kept closing.

2. Private equity went from dabbling to dominating. In 2022, PE deals on our list totaled about $1.6B. In 2025, they hit $21.3B, more than every other category combined, led by TPG and Blackstone's $18.3B take-private of Hologic and KKR's $3B purchase of Karo Healthcare. Hologic went from serial acquirer on our 2024 list to the largest target we have ever covered.

3. Healthcare strategics are the steady buyers. Pharma, medtech, provider and diagnostics companies showed up every single year, from Cooper's $1.6B Generate deal in 2021 to Hologic's two acquisitions in 2024 and Eli Lilly's $2.5B deal in 2025. They buy rather than build, and in 2024 alone they accounted for $7.9B.

4. Consumer and venture-backed buyers fill out the middle. Consumer strategics like Reckitt, Essity, Kimberly-Clark and Pharmavite remain a reliable exit for consumer brands. Their deals on our lists have stayed under $600M a year. Venture-backed companies are buyers too: Ro, Nurx and Kindbody all acquired in 2022, and in 2025 Remedy Meds bought Thirty Madison, itself an acquirer on our 2022 list.

5. Exit paths widened. In 2021, companies like Owlet reached public markets through SPACs. That window shut in 2022. It reopened in 2025 with real IPOs from BillionToOne and Hinge Health. Generalist growth investors arrived too: General Atlantic led Flo's round and Fidelity led Oura's.

6. The arbitrage is still here. Only 0.5% of venture funding goes to women's and sexual health, while there is a huge active acquirer universe. Founders raise early stage VC funding at a discount and sell their companies at a premium. That gap is why we invest at Seed and Series A.

‍

What's next

Over the coming weeks, we'll break down the ten deals that defined 2026. We have already seen more than $23B in transaction value this year, and we expect more to be announced in the coming two months. A few early signals: Organon, a buyer on our very first list in 2021, agreed to be acquired by Sun Pharma at an $11.75B enterprise value. Apollo invested €3B (about $3.4B) for a minority stake in Bayer's contraceptives business. Ferring agreed to buy fertility startup Gameto for up to $1.4B.

If five years have taught us anything, it's that the companies building in women's health today are the acquisition targets of tomorrow. Follow along as we kick off year six.

‍

Continue Reading

Top 10 Deals of 2026: Ferring to Acquire Gameto for up to $1.38B

Every year, Amboy Street highlights the top 10 transactions in women’s health. The splashy news of the week, and the next blog in our series, is Ferring Pharmaceuticals’ agreement to acquire Gameto, a cell-engineering company reimagining IVF, in a deal worth up to $1.38 billion.

Top 10 Deals of 2026: Sun Pharma to Acquire Organon for $11.75B

Every year, Amboy Street highlights the top 10 transactions in women’s health. This year’s series starts with one of the largest women’s health mergers in history.

Top 10 Deals of 2025: Oura’s $11B Valuation and the Rise of Consumer Healthcare

Each year, Amboy Street publishes a Top 10 Deals of the Year series highlighting the most significant transactions in women’s health. For the last blog in the series, we spotlight a watershed deal in women’s health - Oura’s Series E valued at $11B.

Top 10 Deals of 2026: Ferring to Acquire Gameto for up to $1.38B

Every year, Amboy Street highlights the top 10 transactions in women’s health. The splashy news of the week, and the next blog in our series, is Ferring Pharmaceuticals’ agreement to acquire Gameto, a cell-engineering company reimagining IVF, in a deal worth up to $1.38 billion.

Top 10 Deals of 2026: Sun Pharma to Acquire Organon for $11.75B

Every year, Amboy Street highlights the top 10 transactions in women’s health. This year’s series starts with one of the largest women’s health mergers in history.

Fast track our industry.
Get in touch today.